Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Single IV Dose of HSK3486 Injectable Emulsion in Healthy Subjects.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03773835
Recruitment Status : Completed
First Posted : December 12, 2018
Last Update Posted : March 3, 2020
Sponsor:
Information provided by (Responsible Party):
Sichuan Haisco Pharmaceutical Group Co., Ltd.

Brief Summary:
his single-center, open-label, uncontrolled, and dose-escalation study evaluated the safety, tolerability, and pharmacokinetics/pharmacodynamics of single IV dose of HSK3486 injectable emulsion in healthy subjects.

Condition or disease Intervention/treatment Phase
Anesthesia Sedation Drug: HSK3486 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-center, Open-label, Uncontrolled, and Dose-escalation Study Evaluating Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Single IV Dose of HSK3486 Injectable Emulsion in Healthy Subjects.
Actual Study Start Date : May 2016
Actual Primary Completion Date : August 2016
Actual Study Completion Date : August 2016

Arm Intervention/treatment
Experimental: HSK3486
0.15mg/kg, 0.40mg/kg, 0.60mg/kg, 0.90mg/kg,
Drug: HSK3486
Mmanual IV bolus injection completed in 1 minute.




Primary Outcome Measures :
  1. Apnea [ Time Frame: First dose of study drug on day 1 ]
    No movement of chest wall and cessation of end-tidal carbon dioxide waveform > 15 seconds.

  2. Safety by measurement of Adverse Events [ Time Frame: First dose of study drug on day 1 ]

Secondary Outcome Measures :
  1. Modified observer's assessment of alertness/sedation(MOAA/S) [ Time Frame: From first dose of study drug until fully alert on day 1 ]
    Observe the change of modified observer's assessment of alert /sedation during the whole trial

  2. Bispectral index (BIS) [ Time Frame: From first dose of study drug until fully alert on day 1 ]
  3. Median effective dose (ED50) [ Time Frame: From first dose of study drug until fully alert on day 1 ]
  4. Peak concentration (Cmax) [ Time Frame: From the start of administration to 48 hours after administration ]
  5. Time to plasma peak concentration(Tmax) [ Time Frame: From the start of administration to 48 hours after administration ]
  6. Terminal elimination half life (t1/2z) and mean residence time (MRT) [ Time Frame: From the start of administration to 48 hours after administration ]
  7. Mean residence time (MRT) [ Time Frame: From the start of administration to 48 hours after administration ]
  8. Area Under the Curve (AUC0-30min, AUC0-1h, AUC0-last, and AUC0-inf) [ Time Frame: From the start of administration to 48 hours after administration ]
  9. Total clearance (CL) [ Time Frame: From the start of administration to 48 hours after administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy males or females with full capacity for civil conduct, between 18 and 49 years old (inclusive);
  2. Body weight > 45 kg, and body mass index (BMI) ≥ 19 and ≤24 kg/m2;
  3. Blood pressure between 90-140/60-90 mmHg; heart rate between 60-99 bpm; body temperature between 35.8-37.5 ºC; respiration rate between 12-24 breaths per minute; SpO2 when inhaling > 95%;
  4. Normal physical examination, laboratory tests (blood routine, blood biochemistry, and urine routine), 12-Led ECG, posteroanterior and lateral chest x-ray, and or abnormal but without clinical significance (determined by investigator); no potential difficult airway;
  5. Subjects must understand the procedures and methods of this study, and be willing to provide informed consent and to complete the trial in strict accordance with clinical trial protocol.

Exclusion Criteria:

  1. Known sensitivity to propofol, excipient in propofol medium and long chain fat emulsion injection, excipient in HSK3486 injectable emulsion;
  2. contraindicated in general anesthesia;
  3. Received any one of the following medications or treatments prior to screening/enrollment:

    1. History of medication abuse or any signs of chronic benzodiazepines use (such as insomnia, anxiety, spasms) within 3 months prior to screening, or a positive urine medication test (during screening or at baseline);
    2. Participated in clinical trials involving any medications or medical devices within 3 months prior to screening, or participated in 3 or more drug clinical trials within the past year;
  4. History or evidence of increased risk of sedation or anesthesia, such as cardiovascular disease, respiratory disease, cerebrovascular disease, gastrodintestinal disease and other system disease prior to the screening and/or baseline period;
  5. Laboratory results that meet any of the following during screening/enrollment:

    1. Positive for HBsAg, HCV, or HIV;
    2. Abnormal hepatic or renal function confirmed after re-examination;

      • ALT or AST > ULN;
      • Creatinine > ULN;
  6. History of smoking for more than 3 weeks and/or respiratory irritation caused by smoking within 3 months prior to screening;
  7. History of alcohol abuse within 3 months prior to screening or a positive alcohol test (baseline);
  8. Women who are pregnant or breastfeeding; women of child-bearing potential or men who are unwilling to use contraception during the trial;
  9. Subjects judged by the investigator to be unsuitable for participating in this trial for any reason.
Layout table for additonal information
Responsible Party: Sichuan Haisco Pharmaceutical Group Co., Ltd.
ClinicalTrials.gov Identifier: NCT03773835    
Other Study ID Numbers: HSK3486-101
First Posted: December 12, 2018    Key Record Dates
Last Update Posted: March 3, 2020
Last Verified: August 2016

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No